ProHema-CB Transplant
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 11/100
11
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metabolic Disorders
Conditions
Metabolic Disorders
Trial Timeline
Jun 1, 2015 → Feb 1, 2017
NCT ID
NCT02354443About ProHema-CB Transplant
ProHema-CB Transplant is a phase 1 stage product being developed by Fate Therapeutics for Metabolic Disorders. The current trial status is terminated. This product is registered under clinical trial identifier NCT02354443. Target conditions include Metabolic Disorders.
What happened to similar drugs?
19 of 20 similar drugs in Metabolic Disorders were approved
Approved (19) Terminated (4) Active (1)
Hype Score Breakdown
Clinical
6
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02354443 | Phase 1 | Terminated |
Competing Products
20 competing products in Metabolic Disorders